Drug
Adalimumab
Adalimumab: highest development phase Approved, developed by AbbVie, Eli Lilly, United Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- AbbVie, Eli Lilly, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| HUMIRA | Approved | |
| adalimumab NCT01166282 | Phase 3 | Enthesitis Related Arthritis (ERA) |
| Adalimumab NCT01710358 | Phase 3 | Rheumatoid Arthritis |
| Adalimumab NCT01670240 | Phase 3 | Ulcerative Colitis |
| Adalimumab NCT01064856 | Phase 3 | Peripheral Spondyloarthritis |
| Adalimumab NCT01243671 | Phase 3 | Intestinal Behçet's Disease |
| Adalimumab NCT02065570 | Phase 3 | Crohn's Disease |
| Adalimumab NCT03180957 | Phase 2 | Dupuytren's Disease |
Latest
Follow Adalimumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.